An overview of PsoProtect’s current data.
We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.
Click here to read our recently published scientific research paper detailing the PsoProtect data, entitled ‘Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study‘.
Summary data from PsoProtect’s first 374 cases.
Cases reported by country of assessment:
|United Kingdom||135 (36.1%)|
|United States||25 (6.7%)|
|Rest of Europe||22 (5.9%)|
|Rest of the world||21 (5.6%)|
Average age: 50 years
Phenotype of psoriasis: 365 (98%) plaque psoriasis, 8 (2%) pustular psoriasis
Average BMI: 27.4 kg/m2
Average number of days of symptoms from COVID-19: 14 days
Concurrent psoriatic arthritis:
Severity of psoriasis at time of onset of COVID-19 (PGA):
Hospitalization required due to COVID-19:
Systemic medication for psoriasis at time of onset of COVID-19:
|Biologic – TNF inhibitor||99|
|Biologic – IL-23 inhibitor||90|
|Biologic – IL-17 inhibitor||78|
|Conventional systemic agent||39|
|Small molecule inhibitor||26|
|Biologic and conventional systemic co-therapy||15|
|Small molecule inhibitor and conventional systemic co-therapy||2|
|No systemic agent||36|